<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139048">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01290874</url>
  </required_header>
  <id_info>
    <org_study_id>2010p001898</org_study_id>
    <nct_id>NCT01290874</nct_id>
  </id_info>
  <brief_title>Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT)</brief_title>
  <acronym>BELT</acronym>
  <official_title>Blacks and Exacerbations on LABA vs. Tiotropium (BELT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Olmsted Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>American Academy of Family Physicians National Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baim Institute for Clinical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We are doing this study to learn how genes affect the way that people, specifically Black
      people, respond to treatment for asthma. Recent studies suggest that people respond
      differently to some asthma medications (eg Serevent, Foradil). Some people feel better when
      they use these inhalers, but others may not, and some people get worse. It seems that this
      difference shows up more often in Blacks than in Whites, which is why we are looking for
      Black subjects for this study. In all people, this difference seems to depend on their genes
      or DNA. This study is comparing the use of long acting asthma medications (Serevent,
      Foradil) to Tiotropium (Spiriva) for the treatment of asthma. Spiriva is used to treat
      chronic obstructive pulmonary disease (COPD). This study will help to see if this medication
      is also useful for treating asthma and whether it works better for some people than the
      current asthma medications.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Exacerbations</measure>
    <time_frame>evaluated monthly (on average) via questionnaire for 12 months</time_frame>
    <description>We will compare the rate of asthma exacerbations in subjects taking long acting beta agonists (LABA) versus Tiotropium over the one year treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient-reported outcomes (Asthma Quality of Life, Asthma Control, Asthma symptom Utility index, Symptom Free Days)</measure>
    <time_frame>evaluated monthly (on average) via questionnaire for 12 months</time_frame>
    <description>Patient-reported outcomes (Asthma Quality of Life, Asthma Control, Asthma symptom Utility index, Symptom Free Days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spirometry (FEV1)</measure>
    <time_frame>evaluated Visits 1-4 (weeks 0, 4, 26, 52)</time_frame>
    <description>Lung function (FEV1) will be evaluated by spirometry at each visit. (four times over the one year study period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue Medication Use</measure>
    <time_frame>evaluated monthly (on average) via questionnaire for 12 months</time_frame>
    <description>Monthly questionnaires will evaluate the amount of rescue medication subjects have used on average.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Moderate Asthma Deterioration</measure>
    <time_frame>evaluated monthly (on average) via questionnaire for 12 months</time_frame>
    <description>The definition of a moderate asthma deterioration should include one or more of the following: deterioration in symptoms, deterioration in lung function, or increased rescue bronchodilator use. These features should last for 2 days or more, but not be severe enough to warrant systemic corticosteroid use and/or hospitalization.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1071</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Tiotropium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tiotropium bromide will be evaluated as a treatment for asthma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Long Acting Beta Agonist</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Long acting beta agonists (Serevent, Foradil) are the standard treatments for moderate asthma. The efficacy of Tiotropium will be compared to this standard.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium</intervention_name>
    <description>Tiotropium bromide 18 mcg once daily for one year of treatment.</description>
    <arm_group_label>Tiotropium</arm_group_label>
    <other_name>Spiriva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salmeterol</intervention_name>
    <description>Salmeterol 50 mcg twice daily for one year of treatment.</description>
    <arm_group_label>Long Acting Beta Agonist</arm_group_label>
    <other_name>Serevent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol</intervention_name>
    <description>Formoterol 12 mcg twice daily for one year</description>
    <arm_group_label>Long Acting Beta Agonist</arm_group_label>
    <other_name>Foradil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Black (self-identified, with at least one biological parent identified as Black)

          2. Male and female subjects, ages 18-75

          3. Ability to provide informed consent

          4. Clinical history consistent with asthma for &gt; 1 year.

          5. Ability to perform pulmonary function tests

          6. FEV1 &gt; 40% of predicted

          7. Receiving inhaled corticosteroids (ICS)/LABA combination therapy, or ICS moderate
             dose monotherapy and baseline ACQ&gt;1.25

          8. Non-smoker for past year (total lifetime smoking history &lt; 10 pack-years)

        Exclusion Criteria:

          1. Use of greater than the equivalent of 1000 mcg inhaled fluticasone daily

          2. Chronic use of oral corticosteroids or Anti IgE for asthma

          3. Lung disease other than asthma or diagnosis of vocal cord dysfunction.

          4. Significant medical illness (other than asthma) that is not stable.

          5. Pregnancy or lactation or an unwillingness to maintain effective birth control.

          6. History of a significant exacerbation of asthma or respiratory tract infection in the
             prior 4 weeks

          7. History of life-threatening asthma requiring treatment with intubation and mechanical
             ventilation within 5 years.

          8. Hypo sensitization therapy other than an established maintenance regimen.

          9. Use of inhaled anticholinergic therapy (ipratropium, tiotropium) in prior month

         10. Known contraindication to inhaled tiotropium e.g. narrow angle glaucoma, history of
             bladder neck obstruction or significant symptoms related to prostatic hypertrophy.

         11. Inability to speak and read English.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elliot Israel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Edward Waters College Medical Center (Mayo)</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urban Family Practice</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Area Primary Healthcare, Inc</name>
      <address>
        <city>Newton</city>
        <state>Georgia</state>
        <zip>39870</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>G.A. Carmichael F.H.C.</name>
      <address>
        <city>Canton</city>
        <state>Mississippi</state>
        <zip>39046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swope Parkway Health Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Group</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNYNET - Jefferson Family Medicine</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center - NorthEast (Lovelace)</name>
      <address>
        <city>Kannapolis</city>
        <state>North Carolina</state>
        <zip>28081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Medicine Occupational Health Center</name>
      <address>
        <city>Shaker Heights</city>
        <state>Ohio</state>
        <zip>44120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BJHCHS - Hardeeville Medical Center</name>
      <address>
        <city>Ridgeland</city>
        <state>South Carolina</state>
        <zip>29936</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 21, 2015</lastchanged_date>
  <firstreceived_date>December 28, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Elliot Israel, MD</investigator_full_name>
    <investigator_title>Director of the Asthma Research Center</investigator_title>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Blacks</keyword>
  <keyword>LABA</keyword>
  <keyword>Tiotropium</keyword>
  <keyword>Spiriva</keyword>
  <keyword>African American</keyword>
  <keyword>Serevent</keyword>
  <keyword>salmeterol</keyword>
  <keyword>Foradil</keyword>
  <keyword>formoterol</keyword>
  <keyword>Advair</keyword>
  <keyword>Symbicort</keyword>
  <keyword>Dulera</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
